To further validate the involvement of ATP1A1 in resistance to BRAF-targeted therapy, we conducted experiments using three different models of melanoma cell lines (harbouring mutations in cKIT, BRAF or NRAS). The gene discussed is ATP1A1; the disease is melanoma.